24/7 Wall Street
13 Jul 2026, 20:47 UTC · 14w ago
Verdict
Headline takes no side. We score ABT +0.60 across five claims — strongly bullish.
+0.60strongly bullish
More positive than 79% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Pfizer's COVID-related revenues are collapsing, with Comirnaty falling 59% and Paxlovid dropping 62%.
So whatThe loss of a primary revenue engine creates a fundamental valuation gap that requires high-risk pipeline success to fill.
More negative than 99% of claims this week
Pfizer has paused share buybacks and faces $1.5 billion in losses from patent cliffs this year.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 94% of claims this week
Abbott Laboratories completed a $21 billion acquisition of Exact Sciences on March 23, 2026.
More positive than 88% of claims this week
Abbott's Medical Devices segment grew 13.2% in Q1, driven by $2.08 billion in FreeStyle Libre revenue.
More positive than 81% of claims this week
Abbott insiders, including the CFO and a Director, have been purchasing shares near $92.
More positive than 68% of claims this week
Which stocks this story touches
More positive than 79% of ticker scores this week
Despite a YTD price drop, the analyst views it as a stronger risk-adjusted setup with strong medtech growth, insider buying, and a strategic acquisition.
More negative than 74% of ticker scores this week
The analyst describes it as a 'value trap' due to collapsing COVID revenues, patent cliffs, and paused buybacks.
Near neutral — 91% of ticker scores this week are stronger
Mentioned only in the context of price targets without specific sentiment analysis in the main text.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
+9.2%
Price agrees with the score
$100.57 vs $92.11 close before publication (Jul 13) · not market-adjusted
ABT chart →
